Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss

By Zacks Investment ResearchStock MarketsMay 08, 2019 08:51AM ET
Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss
By Zacks Investment Research   |  May 08, 2019 08:51AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Prothena Corporation (NASDAQ:PRTA) reported mixed results for the first quarter of 2019. The company reported a loss of 52 cents per share, narrower than the Zacks Consensus Estimate of a loss of 60 cents and the year-ago quarter’s loss of $1.26.

Quarterly revenues came in at $0.19 million, missing the Zacks Consensus of $0.20 million. Revenues were also down from $0.23 million in the year-ago quarter. Revenues mainly came from the company’s collaboration with Roche Holdings (OTC:RHHBY) .

The company’s shares have lost 0.4% in the year so far compared with the industry’s’ growth of 3.2%.

Quarter in Detail

R&D expenses were $13.3 million, down 61.7% year over year due to lower clinical trial costs, reduced consulting and personnel costs, and decreased product manufacturing expenses.

General and administrative (G&A) expenses came in at $9.9 million, down from $14.2 million in the year-ago quarter.

As of March 31, 2019, Prothena had $414.2 million in cash, cash equivalents and restricted cash.

Pipeline Updates

The company is evaluating prasinezumab (PRX002/RG7935) in collaboration with Roche for the treatment of Parkinson’s disease. A phase II study, PASADENA, which is being conducted by Roche among patients suffering from Parkinson`s disease, is ongoing and data from the part I study is expected in 2020.

Also, Prothena initiated a phase I study on PRX004 in patients with hereditary ATTR amyloidosis in the second quarter of 2018. The study continues to enroll patients. Preliminary data from lower dose cohorts, including safety, tolerability and pharmacodynamics, are expected in the fourth quarter of 2019.

Prothena has a global neuroscience research & development collaboration with Celgene Corp. (NASDAQ:CELG) to develop new therapies for a broad range of neurodegenerative diseases. The collaboration is focused on three targets implicated in the pathogenesis of several neurodegenerative diseases, inducing tau, TDP-43 and a third that is undisclosed. The preclinical tau program, part of a worldwide collaboration with Celgene, initiated cell line development of a lead candidate.

The company recently reported results from the phase III VITAL study of NEOD001 in AL amyloidosis and the company is exploring business development opportunities that could result in further clinical investigation of NEOD001.

Our Take

The narrower-than-expected loss in the first quarter was encouraging for Prothena. We expect investors’ focus to remain on pipeline updates, as the company has no approved product in its portfolio yet. Moreover, the company earlier had discontinued the development of its lead pipeline candidate, NEOD001. Prothena has very limited number of candidates in its pipeline. Now, investors are likely to focus on the ongoing phase II study of prasinezumab, though results from the mid-stage study on this candidate are not expected before 2020.

Zacks Rank & Stock to Consider

Prothena currently carries a Zacks Rank #3 (Hold).

A better-ranked stock in the healthcare sector is Bristol-Myers Squibb (NYSE:BMY) , which sports a Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Bristol-Myers’ earnings per share estimates have increased from $4.76 to $4.93 for 2020 in the past 60 days.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Roche Holding (SIX:ROG) AG (RHHBY): Free Stock Analysis Report

Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report

Celgene Corporation (CELG): Free Stock Analysis Report

Prothena Corporation plc (PRTA): Free Stock Analysis Report

Original post

Zacks Investment Research
Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss

Related Articles

Prothena's (PRTA) Q1 Earnings Beat Estimates, Revenues Miss

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
Sign up with Email